Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06966388 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

A Phase 1 study of Breast Cancer, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
Phase 1
Development phase
33
Enrollment target
1
Study location

NCT06966388: Recruiting Phase 1 study of Breast Cancer, sponsored by Virginia Commonwealth University.

NCT06966388 is a Phase 1 study of Breast Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 33 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06966388, a Phase 1 study of Breast Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

Primary Outcome

The percentage of days patients used azelaic acid at least once.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Azelaic Acid

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2025-08-13
Est. Completion 2026-11-30
Phase Phase 1
Virginia Commonwealth University

558 total trials

What NCT06966388 shows while recruiting

NCT06966388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Azelaic Acid is the first listed.

NCT06966388 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06966388 about?

NCT06966388 is a clinical study titled "Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation". This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

What is the current status of trial NCT06966388?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-08-13. Estimated completion is 2026-11-30.

What conditions does trial NCT06966388 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06966388?

The interventions under investigation include: Azelaic Acid (DRUG).

Who is sponsoring clinical trial NCT06966388?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06966388 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06966388's enrollment target sits among peer trials

33 935th of 1224 higher than 285 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06966388

Source: ClinicalTrials.gov NCT06966388, the US trial registry maintained by the National Library of Medicine. NCT06966388 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.